France’s Gemme Unveils Three-Point Plan To Bolster Biosimilars
As Biosimilar Penetration Falls Short Of Government’s ‘Ambitious’ Target
Executive Summary
Fresh impetus is needed to help biosimilars achieve their full potential in France, according to off-patent industry association Gemme. The organization has unveiled a three-point plan to bolster the sector that includes proposals to allow pharmacists to substitute biosimilars for brand prescriptions under certain circumstances.